Sacituzumab Govitecan in HR+/HER2- Metastatic or Domestically Recurrent Breast Most cancers


Video content material above is prompted by the next query:

  • Please touch upon the affected person inhabitants, research design and key goals from the part 3 TROPiCS-02 research of sacituzumab govitecan in sufferers with HR+/HER2- metastatic or regionally recurrent inoperable breast most cancers.

Hot Topics

Related Articles